Director/Head, RWE Strategy/Analytics & Epidemiology | New Role | Top Oncology Biotech | NJ / PA: RETAINED SEARCH

Cornerstone Search Group
Published
May 11, 2021
Location
Greater New York City Area, United States of America
Category
Job Code
csaNH3001csg
Contact Email
cackerman@cornerstonesg.com

Description

Director/Head, RWE Strategy/Analytics & Epidemiology | New Role | Top Oncology Biotech | NJ / PA: RETAINED SEARCH

ABOUT THE JOB:

Cornerstone Search Group’s HEOR/RWE/Market Access Practice has been retained by the Head of HEOR/RWE/Epi (whom we have helped hire before) at one of the industry’s most exciting and fastest growing oncology biotechs (multiple approved biologics, 20+ asset self-developed pipeline, fast growing stock) for a newly-created and well-compensated Director-level position to create and lead data strategy, infrastructure (including building a team) and operations for both Real World Evidence and Epidemiology (post-approval observational studies, pre/post approval risk assessment, etc.). Expertise in either RWE Analytics or Epi is required, but not both. Oncology experience is a plus, but not required.

HIGHLY ATTRACTIVE FEATURES OF THIS OPPORTUNITY:

(1) “Best of Both Worlds”: Enjoy the benefit of working in a smaller, entrepreneurial, fast-moving environment where you will work with senior management while simultaneously enjoy the stability and security of working for a highly successful company with the stability afforded by their financial strength (large market cap, fast growing stock price, billion+ in revenue,) are that of a much larger company), and a huge and innovative pipeline that has attracted strong industry veterans from top large pharmas.

(2) Innovative Self-Discovered 20+ Asset Pipeline: Our client’s vast pipeline is self-developed and built upon their own multiple antibody engineering platforms. Their monoclonal antibody, ADC, and bi-specific antibody therapeutics are all cutting edge and designed to provide a significant advancement in patient care.

(3) Company’s Stock Performance and Annual Stock Plan: Our client is one of the strongest performing pharma stocks over the last 5 years. In comparison, most large pharma stocks have stagnated over the last couple of years. Our client is very proud of providing their employees with significant stock awards (far superior to Big Pharma) so that their team feels really valued for the role they will play in building the company’s future.

(4) Employer of Choice: Their fast-rising stock price, top-tier annual stock awards (far superior to what Big Pharma provides), robust and diverse next-generation self-discovered pipeline, their financial strength, and their culture has made our client one of the industry’s top “Employers of Choice”.

LOCATION: New Jersey / Pennsylvania Metro Area

Our client is conveniently located for people who live in either New Jersey or Pennsylvania. This scenic area is home to many other pharma and biotech companies, affordable housing options (a lot less expensive than California or Massachusetts), and is considered to have some of the best public-school districts in the country.

RELOCATION: Our client can offer an attractive relocation plan for a post-COVID relocation in 2022. In the meantime, our client is not requiring people to work on-site.

SCOPE OF RWE AND EPIDEMIOLOGY RESPONSIBILITIES:

  • Develop company’s real world data strategy.
  • As a key foundational block of the CORE (Center for Outcomes Research, Real World Evidence, and Epidemiology) department, you will be counted upon by the Head of CORE (whom this position reports to) to contribute to department strategy and objectives as well as represent CORE on key initiatives.
  • Develop their RWE platforms with current external RWE partner and architect for future where platforms and people move in-house under your leadership.
  • Partner with HEOR asset leads on the development and execution of RWE studies and with Drug/Safety PV on post-approval study commitments.
  • Educate the organization on applicable regulations to the execution of RWE and Epidemiology.
  • Define and implement Observational Study Review Committee that will be responsible for the scientific review of observational studies.
  • Foster learning and drive RWE innovation through developing awareness and the application of impactful use cases of RWE.
  • Develop scientific standards and infrastructure for pre-and post-approval drug risk assessment (e.g.: Post-Marketing Surveillance and PASS studies using observational study designs) and the evaluation of risk management activities.
  • Define and develop operational infrastructure needs and standards for post-approval prospective observational studies.
  • Support assets by generating the evidence in a strategic manner for: (1) assessing product safety, risk management, post-marketing safety; and (2) input into regulatory documents that require epidemiologic expertise (e.g.: RMP, DSUR, PBRER)

DESIRED SKILLS / QUALIFICATIONS / EXPERIENCE:

  • PhD / PharmD / MPH / MS degree in relevant field (Epidemiology, Health Services Research, Statistics, etc.)
  • Seeking 5+ years of relevant experience in RWE for HEOR or Post-Approval Epidemiology purposes, either for a pharmaceutical/biotech company, an agency / CRO / consulting company working with pharma clients, a managed care company, or in academia.
  • Oncology experience is a plus, but not required.

DESIRED PERSONAL TRAITS:

  • Seeking someone with a strategic clinical and commercial mindset, leadership capabilities, a desire to work in a fast-paced environment, and a pro-active desire to build the company’s in-house RWE and Epi capabilities.
  • Seeking someone who will fit in with their culture: people who are passionate about what they do, self-motivated, desire to make an impact, and want to work on an innovative pipeline that significantly advances the standard of care for cancer patients.
  • The ability to communicate technical information in a clear and concise way to diverse audiences (C-level, Commercial, Med Affairs, etc.) and effectively manage internal and external stakeholder expectations.

CONTACT:

Corey S. Ackerman, JD | Senior Partner

E: cackerman@cornerstonesg.com | P:  973.656.0220 x716

LinkedIn: www.linkedin.com/in/coreyackerman

Rita Boyle | Partner

E: rboyle@cornerstonesg.com | P: 973.656.0220 x735

LinkedIn: https://www.linkedin.com/in/ritaboyle

CORNERSTONE SEARCH GROUP – Life Sciences Executive Search

6 Campus Drive | Suite 301 | Parsippany, NJ 07054 USA

www.cornerstonesg.com | 973.656.0220

Examples of Retained Search Assignments:

  • CEO | specialty start-up
  • US CEO | established European small pharma
  • CMO | late-stage public biotech
  • CMO | mid-size pharma
  • CSO | mid-size global biotech
  • President/US Commercial Head | OSD generics
  • SVP, Head of Global Medical Affairs | mid-size oncology company
  • SVP, Head of Global Regulatory Affairs | late-stage Israeli biotech
  • Group VP, Global Commercial Head | API Business Unit | Indian pharma
  • VP, Global Head of Biometrics | NYC commercial-stage biotech
  • VP, Head of Regulatory Affairs | Boston biotech
  • VP, Head of Regulatory Affairs | NYC commercial-stage biotech
  • VP, Head of R&D Operations | Boston biotech
  • VP, Head of Health Economics & Outcomes Research | Top CNS specialty pharma
  • VP, Head of Real-World Evidence | Top 5 pharma
  • VP, Head of Heme/Onc Clinical Research | Public oncology biotech
  • Executive Director, Head of Global Clinical Pharmacology | Public oncology biotech
  • Executive Director, Head of Global Clinical Pharmacology | Public oncology biotech
  • Executive Director, Head of US Drug Safety & PV | Chinese oncology biotech
  • Medical Director, Clinical Development | Boston biotech
  • Medical Director, Translational Medicine, Neuroscience | Top 5 Biotech

Cornerstone’s Privacy Policy: Cornerstone Search Group considers all inquiries, resume submissions, and any other personal information submitted to us as confidential information. This information will not be shared with any parties outside of Cornerstone Search Group without your prior permission.

Keywords: senior director, executive director, mAb, monoclonal antibody, bsab, bispecific, bi-specific, antibody drug conjugates, ADC, immune-onc, immuno-onc, immuno oncology, IO, breast cancer, lung cancer, NSCLC, ovarian cancer, cervical cancer, bladder cancer, colon cancer

Apply
Drop files here browse files ...
PDF and .doc resume uploads are preferred. docx files are not supported.
Captcha